CD274 and diffuse large B-cell lymphoma: Since PD1/PDL1-based immunotherapy showed promising efficacy in part of CNS DLBCL (39), it is possible that CDP group may be more sensitive to immune checkpoint inhibitor treatment than non-CDP group, which deserve further exploration.